Evidence map›Paper›PMID 42160341›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15.

Justin A Shyer, Fabien Wehbe, Christopher D Davidson, Hannah S Bender, Minh Thai, Christian Cox, Alsu Missarova, Alexander Arlantico, Ben Hall, Ruoyu Zhang and 25 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. LRRC15+ Myofibroblasts as a Stromal State Linking Repair, Fibrosis, and Scarring.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Justin A Shyer *Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Fabien Wehbe *Roche Informatics, F. Hoffmann-La Roche Ltd., Mississauga, ON L5N 5M8, Canada.
Christopher D Davidson *Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Hannah S BenderGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Minh ThaiGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Christian CoxGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Alsu MissarovaGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Alexander ArlanticoGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Ben HallGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Ruoyu ZhangGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
David KimGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Anthony AltieriDepartment of Immunology, University of Toronto, Toronto, ON M5S 3G9, Canada.
Shakir HasanDepartment of Immunology, University of Toronto, Toronto, ON M5S 3G9, Canada.
Afshin NamdarDepartment of Immunology, University of Toronto, Toronto, ON M5S 3G9, Canada.
Tina ChenHospital for Sick Children Research Institute, Toronto, ON M5G 1E8, Canada.
Shaheed W HakimSt. Joseph's Health Centre, Unity Health Toronto, Toronto, ON M6R 1B5, Canada.
Cynthia GuidosHospital for Sick Children Research Institute, Toronto, ON M5G 1E8, Canada.ORCID 0000-0002-7674-2612
Hans D BrightbillGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Tony KuoRoche Informatics, F. Hoffmann-La Roche Ltd., Mississauga, ON L5N 5M8, Canada.
Graham HeimbergGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Héctor Corrada BravoGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Rojo A RatsimandresyGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Salil UttarwarGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Grace TengGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Omar SalemGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Mehrdad ArjomandiDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143.
Mark S WilsonGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Spyros DarmanisGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
James ZiaiGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Alexis ScherlGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.ORCID 0000-0001-6130-3118
Zora ModrusanGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.
Paul J WoltersDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143.ORCID 0000-0002-3108-6164
Matthew B BuechlerDepartment of Immunology, University of Toronto, Toronto, ON M5S 3G9, Canada.
Jason A Vander HeidenGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.ORCID 0000-0002-1474-310X
Shannon J TurleyGenentech Research and Early Development, Genentech, Inc., South San Francisco, CA 94080.

Funding

Canadian Institutes of Health Research (CIHR) 471606Roche Holding | Genentech (Genentech USA) N/A
6 · The paper itself

Abstract

Fibroblasts are key potentiators of chronic disease pathophysiology. Despite their established roles in promoting pathological inflammation and tissue remodeling, activated myofibroblasts are generally characterized as a single, homogeneous cell population, obscuring critical functional distinctions. Defining the cell states, their molecular regulators, and restricted markers is critical to developing effective therapies for the treatment of fibrosis. Here, using a human lung stromal cell atlas of idiopathic pulmonary fibrosis, we identify two myofibroblast transcriptional states associated with distinct predicted biological function, regulation, and cell surface marker expression. We identify fibroblast-specific TGFb signaling as the key regulator of the mechanistic switch from a wound healing-associated and proliferative to a profibrotic myofibroblast. Further, we elucidate conserved TGFb-dependent and suppressed gene expression programs that define these states. Our findings reveal that LRRC15 is highly restricted to myofibroblasts that primarily express an extracellular matrix-remodeling gene program and illuminate that this key cell state can differentiate in the absence of an obligate inflammatory precursor intermediate. Last, we apply machine learning using a human single-cell foundation model to demonstrate broad applicability of the biology described herein to human chronic disease.

Indexed as

Idiopathic Pulmonary FibrosisMembrane ProteinsMyofibroblastsSignal TransductionTransforming Growth Factor betaExtracellular MatrixFibroblastsFibrosisGene Expression RegulationHumansWound HealingMembrane ProteinsTransforming Growth Factor betafibrosisinflammationmyofibroblastTGFbwound healing

Identifiers

PMID42160341
PMCPMC13214008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.